Promising phase I results against new HIV target.
Whelan
Jo
J
D044966:Anti-Retroviral Agents / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D024882:Drug Resistance, Viral; D015683:Gene Products, gag / Q000037:antagonists & inhibitors*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D013386:Succinates / Q000494:pharmacology*; D014315:Triterpenes / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects; D053978:Pentacyclic Triterpenes
D044966:Anti-Retroviral Agents; D015683:Gene Products, gag; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes